Phosphor screen scanners are medical imaging devices used in diagnostic applications such as radiography and computed radiography to scan phosphor plates and generate digital images. They find extensive applications in various healthcare settings including hospitals, specialty clinics, diagnostic centers, and imaging centers. With rising prevalence of chronic and lifestyle diseases, diagnostic volumes have increased exponentially, driving the demand for medical imaging equipment. Adoption of computed and digital radiography modalities over traditional photography-based processes has further propelled the sales of phosphor screen scanners.
The global phosphor screen scanner market is estimated to be valued at US$ 288 Bn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics
The increasing demand can be attributed to two major drivers. Firstly, growing geriatric population prone to various age-related diseases and injuries has significantly contributed to the rising diagnostic volumes. As per estimates, over 16% of world’s population will be aged 65 years and above by 2050. This provides a steady patient base for medical imaging requirements. Secondly, improving access to healthcare through favorable public and private initiatives in developing nations has enhanced the penetration of diagnostic technologies. Asia Pacific region in particular has emerged as a lucrative market for vendors with rapid infrastructure development and growing medical tourism industry.
However, industry players face some challenges from alternative imaging modalities and privacy & security concerns. Digital X-Ray, MRI, Ultrasound and Nuclear Imaging offer competitive solutions to conventional radiography. Also, maintaining confidentiality of patient data and preventing cyber-attacks on networked devices remains a key area of focus for developers. Nevertheless, ongoing R&D towards upgraded systems with better image quality, automation, and data management capabilities is expected to sustain the demand over the forecast period.
Segment Analysis
The global Phosphor Screen Scanner market size is segmented into portable and fixed type scanner. The portable scanner segment accounts for over 60% market share and is expected to remain the dominant segment during the forecast period. Portable scanners provide high mobility and ease of use which makes them popular among healthcare professionals and researchers for point-of-care diagnostics and field research applications.
PEST Analysis
Political: Regulations promoting precision medicine and biomarker-based diagnostics in key markets will boost demand. Stringent quality standards ensure reliability of test results.
Economic: Rising healthcare R&D budgets and growing demand for personalized medicine drive market growth. However, pricing pressures may limit premium product purchases.
Social: Increasing incidence of cancer and other diseases raises need for advanced diagnostics. Growing awareness about customized treatment increases uptake.
Technological: Integration of AI and machine learning enhances image analysis capabilities. Ongoing innovations to improve resolution, efficiency, and portability widens applications.
Key Takeaways
The global Phosphor Screen Scanner market is expected to witness high growth during the forecast period due to increasing investments in healthcare R&D and growing adoption of precision medicine.
North America represents the largest regional market owing to presence of key players, advanced research infrastructure, and higher adoption of new diagnostic technologies among healthcare facilities in the region.
Key players operating in the Phosphor Screen Scanner market are Intomics, GENinCode, NanoString, Tepnel Pharma Services Limited, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc, QIAGEN, Quest Diagnostics Incorporated, Medtronic, Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, bioMérieux SA, F. Hoffmann-La Roche Ltd, Eli Lilly & Company, GlaxoSmithKline plc, Cepheid, AstraZeneca PLC, Myriad Genetics, Inc., Bristol-Myers Squibb Company, and Foundational Medicine.